BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $12
Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger With Exscientia: Upside Potential Amidst Clinical Uncertainties
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Recursion Pharmaceuticals Analyst Ratings
Strategic Mergers and Financial Strength: Recursion Pharmaceuticals' Path to Growth
Recursion Pharmaceuticals' Strategic Acquisition and Leadership Changes